MN
Therapeutic Areas
Cytokinetics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| MYQORZO (aficamten) | Obstructive Hypertrophic Cardiomyopathy | Commercial |
| Aficamten | Obstructive HCM (Monotherapy vs SOC) | Phase 3 |
| Omecamtiv Mecarbil | Heart Failure with Reduced Ejection Fraction | Phase 3 |
| Ulacamten (CK-586) | Heart Failure with Preserved Ejection Fraction | Phase 1 |
| CK-136 | Heart Failure | Phase 1 |
| Reldesemtiv | Amyotrophic Lateral Sclerosis | Phase 3 |
| CK-089 | Fast Skeletal Muscle Troponin Activator | Phase 1 |